Beta-glucan Assay Quantification via Relative Antibody Units
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring anti-β-glucan antibodies in serum samples are limited by their inability to provide exact quantification and are not suitable for clinical applications due to complexity and impracticality, particularly in assessing immune response to β-glucan-based therapies.
Innovation Solution
A simple ELISA-based method that quantitatively measures anti-β-glucan IgG and IgM antibodies using Relative Antibody Units (RAU) or concentrations, allowing for the identification of biomarker-positive subjects by determining specific cutoff values that correlate with immune response and clinical outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for measuring anti-β-glucan antibodies are used, then immune response assessment is possible, but exact quantification cannot be provided and the methods are too complex for clinical applications
Solution Approach 1:
The patent transforms the measurement output from qualitative/semi-quantitative results to exact quantitative values by introducing Relative Antibody Units (RAU) calculated through a standardized formula using optical density ratios and reference sample values. This parameter transformation enables precise quantification while maintaining procedural simplicity
Solution Approach 2:
The patent creates a simplified model system using ELISA that replicates the essential measurement function without the complexity of original methods. By using enzyme-linked immunosorbent assay with standardized reference samples and calculation formulas, it produces quantifiable results that copy the functional output needed for clinical decision-making
2Reliability
If current antibody measurement methods are used, then immune response detection is possible, but the methods are not suitable for clinical applications due to impracticality
Solution Approach 1:
The patent divides the measurement process into distinct, manageable segments: sample preparation, ELISA assay execution, optical density measurement, and RAU calculation. Each segment can be independently optimized and validated, making the overall method more reliable and easier to implement in clinical settings
Solution Approach 2:
The patent develops a universal ELISA-based method that can measure different types of anti-β-glucan antibodies (IgG, IgM) using the same procedural framework and calculation approach. This multi-functional capability increases reliability across different clinical scenarios while maintaining ease of operation through standardized protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the reliable identification of subjects likely to respond to β-glucan immunotherapy, facilitating personalized treatment approaches and improving clinical outcomes by distinguishing between high and low responders.
Implementation Method 1
analyzing the sample for a biomarker anti-β-glucan antibody using an enzyme-linked immunosorbent assay (ELISA)
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to β-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-β-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-β-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-β-glucan antibody.